Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
ARA-290 (Cibinetide) (ARA290) is a healing peptide, at the phase 2 clinical trials stage in the published literature. ARA-290, also known as Cibinetide, is a novel peptide that represents a breakthrough in separating the tissue-protective properties of erythropoietin from its blood cell-stimulating effects. Developed by Araim Pharmaceuticals, the peptide is an 11-amino acid linear sequence derived from the helix B surface of EPO. It selectively activates the innate repair receptor (IRR) — a heterodimer of the EPO receptor and the beta common receptor (CD131) — which is expressed on damaged or stressed tissues. This selectivity means ARA-290 promotes healing and reduces inflammation without the dangerous side effects of EPO such as blood thickening and tumor growth. Phase 2 clinical trials have been completed for sarcoidosis-related neuropathy and diabetic neuropathy, showing improvements in nerve fiber density and neuropathic symptoms.
ARA-290, also known as Cibinetide, is a novel peptide that represents a breakthrough in separating the tissue-protective properties of erythropoietin from its blood cell-stimulating effects. Developed by Araim Pharmaceuticals, the peptide is an 11-amino acid linear sequence derived from the helix B surface of EPO. It selectively activates the innate repair receptor (IRR) — a heterodimer of the EPO receptor and the beta common receptor (CD131) — which is expressed on damaged or stressed tissues. This selectivity means ARA-290 promotes healing and reduces inflammation without the dangerous side effects of EPO such as blood thickening and tumor growth. Phase 2 clinical trials have been completed for sarcoidosis-related neuropathy and diabetic neuropathy, showing improvements in nerve fiber density and neuropathic symptoms.
| Research Status | Phase 2 Clinical Trials |
|---|---|
| Half-Life | 2-3 minutes (rapid clearance) |
| Administration | Subcutaneous injection, Intravenous |
| Doses Reported in Published Studies | 2-4 mg |
| Molecular Weight | 1,257.4 Da |
| Molecular Formula | C50H88N16O22 |
ARA-290 binds to the innate repair receptor (IRR), a heterodimer of EPO receptor and CD131/βc receptor, triggering anti-inflammatory and tissue-protective signaling cascades including JAK2/STAT5, PI3K/Akt, and NF-κB suppression, without stimulating red blood cell production.
ARA-290, also known as Cibinetide, is a novel peptide that represents a breakthrough in separating the tissue-protective properties of erythropoietin from its blood cell-stimulating effects. Developed by Araim Pharmaceuticals, the peptide is an 11-amino acid linear sequence derived from the helix B surface of EPO. It…
ARA-290 binds to the innate repair receptor (IRR), a heterodimer of EPO receptor and CD131/βc receptor, triggering anti-inflammatory and tissue-protective signaling cascades including JAK2/STAT5, PI3K/Akt, and NF-κB suppression, without stimulating red blood cell production.
ARA-290 (Cibinetide) is at the following stage in the published literature: Phase 2 Clinical Trials. All information is for research and educational purposes only.
Reported half-life: 2-3 minutes (rapid clearance).
Reported administration route in the literature: Subcutaneous injection, Intravenous. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.